Claims for Patent: 7,858,335

Summary for Patent: 7,858,335

Title:	Microorganisms and assays for the identification of antibiotics
Abstract:	The present invention features methods for the identification of compounds and compositions useful as antibiotics and antibacterial agents. In particular, the invention features methods for the identification of modulators of a previously unidentified target protein, termed CoaX. High-throughput assay systems are featured as well as assay kits for the identification of CoaX modulators. Also featured are coaX nucleic acid molecules and purified CoaX proteins, as well as recombinant vectors and microorganisms including the gene, coaX.
Inventor(s):	Yocum; R. Rogers (Lexington, MA), Patterson; Thomas A. (North Attleboro, MA)
Assignee:	OmniGene Bioproducts, Inc. (Woburn, MA)
Application Number:	11/709,370
Patent Claims:	1. A method for identifying compounds that inhibit pantothenate kinase activity, comprising: a) contacting a cell comprising a recombinant expression vector expressing a CoaX protein having pantothenate kinase activity with a test compound, wherein said CoaX protein is encoded by a naturally-occurring, microbial coaX gene; and b) determining the ability of the test compound to inhibit pantothenate kinase activity in said cell; wherein inhibition of pantothenate kinase activity identifies the compound as an inhibitor of pantothenate kinase activity. 2. The method of claim 1, wherein the recombinant cell is dependent on the CoaX protein for growth. 3. The method of claim 1, wherein the recombinant cell is not dependent on the CoaX protein for growth. 4. The method of claim 1, wherein the recombinant cell further comprises a CoaA protein endoced by a coaA gene. 5. The method of claim 4, wherein the CoaA protein is expressed from a recombinant expression vector. 6. A method for identifying compounds that inhibit CoaX pantothenate kinase activity, comprising: a) contacting a cell comprising a recombinant expression vector expressing a CoaX protein having pantothenate kinase activity encoded by a naturally-occurring, microbial coaX gene with a test compound, wherein said cell is dependent on the CoaX protein encoded by the coaX gene for growth; b) determining the ability of the test compound to inhibit growth of said cell; and c) comparing the ability of the cell comprising the recombinant expression vector expressing the CoaX protein encoded by the coaX gene to grow with the ability of a cell comprising a CoaA protein encoded by a coaA gene to grow; wherein the inability of the cell comprising the recombinant expression vector expressing the CoaX protein encoded by the coaX gene to grow and the ability of the cell comprising the CoaA protein encoded by the coaA gene to grow identifies the compound as an inhibitor of CoaX pantothenate kinase activity. 7. The method of claim 4 or 6, wherein the cell comprising the CoaA protein encodes a pantothenate kinase polypeptide with reduced activity. 8. The method of claim 7, wherein said reduced pantothenate kinase activity is due to an environmental manipulation. 9. The method of claim 4 or 6, wherein the CoaA protein is expressed from a recombinant expression vector. 10. The method of claim 1 or 6, wherein said cell comprising the recombinant expression vector expressing the CoaX protein is a Gram negative microorganism. 11. The method of claim 1 or 6, wherein said cell comprising the recombinant expression vector expressing the CoaX protein is a Gram positive microorganism. 12. The method of claim 6, wherein said cell comprising the CoaA protein is a Gram negative microorganism. 13. The method of claim 6, wherein said cell comprising the CoaA protein is a Gram positive microorganism. 14. The method of claim 1 or 6, wherein said cell comprising the recombinant expression vector expressing the CoaX protein is of the genus Bacillus or Escherchia. 15. The method of claim 1 or 6, wherein said cell comprising the recombinant expression vector expressing the CoaX protein is Bacillus subtilis or Escherchia coli. 16. The method of claim 6, wherein said cell comprising the CoaA protein is of the genus Bacillus or Escherchia. 17. The method of claim 6, wherein said cell comprising the CoaA protein is Bacillus subtilis or Escherchia coli. 18. The method of claim 1 or 6, wherein said cell comprising the recombinant expression vector expressing a CoaX protein is a non-pathogenic bacterium and said coaX gene is derived from a pathogenic bacterium. 19. The method of claim 1 or 6, wherein the recombinant expression vector is selected from the group consisting of pAN296 (SEQ ID NO: 71), pAN336 (SEQ ID NO: 72), pOTP71 (SEQ ID NO: 75), pOTP72 (SEQ ID NO: 76), pOTP73 (SEQ ID NO: 77), and pAN341 (SEQ ID NO: 73). 20. The method of claim 1 or claim 6, wherein the coaX gene is a coaX gene from a pathogenic bacterium selected from the group consisting of Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, Clostridium difficile, Helicobacter pylori, Neisseria meningitidis, Pseudomonas aeruginosa, Treponema pallidumu and Xylella fastidiosa. 21. The method of claim 1 or claim 6, wherein the coaX gene is a coaX gene from a pathogenic bacterium selected from the group consisting of Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, Clostridium difficile, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae, Porphyromonas gingivalis, Pseudomonas aeruginosa, Treponema pallidum and Xylella fastidiosa. 22. The method of claim 1 or claim 6, wherein the coaX gene is a coaX gene from a bacterium selected from the group consisting of Aquifex aeolicus, Bacillus anthracis, Bacillus halodurans, Bacillus stearothermophilus, Bacillus subtilis, Caulobacter crescentus, Chlorobium tepidum, Clostridium acetobutylicum, Dehalococcoides ethenogenes, Deinococcus radiodurans, Desulfovibrio vulgaris, Geobacter sulfurreducens, Pseudomonas syringae, Pseudomonas putida, Rhodobacter capsulatus, Thiobacillus ferrooxidans, Streptomyces coelicolor, Synechocystis sp., Thermotoga maritima, Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, Clostridium difficile, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae, Porphyromonas gingivalis, Pseudomonas aeruginosa, Treponema pallidum, Xylella fastidiosa and Mycobacterium tuberculosis.

Details for Patent 7,858,335

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2020-08-24